A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
for
Cervical Squamous Cell Carcinoma,
Location: New Haven CT, Hackensack NJ, Fairfax VA, Louisville KY,
Sponsor: Alentis Therapeutics AG
Sex: All
Age: 18+
Code: NCT07169734
Phase1, Phase2, Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
for
Breast Cancer, Ovarian Cancer, Endometrial Cancer,
Location: Fairfax VA, Houston TX, San Antonio TX, Los Angeles CA
Sponsor: Regor Pharmaceuticals Inc.
Sex: All
Age: 18+
Code: NCT07524322
Phase1, Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
for
Non-small Cell Lung Cancer, Colorectal Carcinoma,
Location: Boston MA, New York NY, Philadelphia PA, Pittsburgh PA,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06218914
Phase1, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
for
Urothelial Carcinoma Bladder,
Location: New York NY, Glen Burnie MD, Miami FL, Pittsburgh PA,
Sponsor: Aktis Oncology, Inc.
Sex: All
Age: 18+
Code: NCT07020117
Phase1, Recruiting
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
for
Head and Neck Squamous Cell Carcinoma (HNSCC),
Location: New York NY, Columbus OH, Grand Rapids MI,
Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Sex: All
Age: 18+
Code: NCT05985655
Phase1, Phase2, Recruiting
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
for
Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors,
Location: Lake Success NY, New York NY, Morristown NJ, Tamarac FL,
Sponsor: Eikon Therapeutics
Sex: All
Age: 18+
Code: NCT07262619
Phase1, Phase2, Recruiting
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
for
Metastatic Solid Tumor, Recurrent Solid Tumor,
Location: Boston MA, New York NY, Cleveland OH, Grand Rapids MI,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06465069
Phase1, Recruiting
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer